Citius Oncology, Inc. CTOR Merger-related charges and other
Merger-related charges and other at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NoncashMergerRelatedCosts.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s merger-related charges and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Citius Oncology, Inc.'s merger-related charges and other?
- Citius Oncology, Inc. (CTOR) reported merger-related charges and other of $2.75M in Q4 2025.
- What does merger-related charges and other mean?
- Includes non-cash expenses incurred during the integration of acquired businesses, such as asset write-downs or accounting adjustments. Identifying these costs allows investors to isolate core operating performance from the impact of one-time acquisition events.